News
MRKR
0.3688
-1.23%
-0.0046
Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.
Benzinga · 20h ago
Why Sunlight Financial Shares Are Trading Lower By 59%, Here Are 54 Stocks Moving In Thursday's Mid-Day Session
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares jumped 52% to $2.1325 after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.
Benzinga · 1d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Pulmatrix (NASDAQ:PULM) shares rose 11.9% to $4.3 during Wednesday's after-market session. The company's market cap stands at $14.5 million.
Benzinga · 09/21 21:36
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 09/19 12:44
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 09/14 12:08
Marker Therapeutics awarded $2M FDA grant for leukemia candidate
Marker Therapeutics, Inc. (NASDAQ:MRKR), a biotech focu...
Seekingalpha · 09/13 11:35
BRIEF-Marker Therapeutics Awarded $2 Million Grant From U.S. FDA To Support Marker’S Phase 2 Artemis Trial Of MT-401 In Post-Transplant Aml
BRIEF-Marker Therapeutics Awarded $2 Million Grant From U.S. FDA To Support Marker’S Phase 2 Artemis Trial Of MT-401 In Post-Transplant Aml
Reuters · 09/13 11:03
Marker Therapeutics Secures $2 Million Grant from US FDA for its Phase 2 ARTEMIS Trial of MT-401
Marker Therapeutics Secures $2 Million Grant from US FDA for its Phase 2 ARTEMIS Trial of MT-401
MT Newswires · 09/13 07:36
Why ShiftPixy Surges Around 177%; Here Are 71 Biggest Movers From Yesterday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.
Benzinga · 09/09 08:13
FDA Grants Phase 2 Study Of Multi-Tumor-Associated Antigen-Specific T Cell Therapy (Mt-401) In Treatment Of Relapsed/Refractory AML
https://www.accessdata.fda.gov/scripts/opdlisting/oopdgrants/OOPD_Grants_Results_2.cfm
Benzinga · 09/08 18:13
Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference
HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies a...
GlobeNewswire · 09/08 11:00
Why AMC Entertainment Is Trading Lower By 33%; Here Are 31 Stocks Moving Premarket
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares rose 48.5% to $0.56 in pre-market trading. Kiromic Biopharma said the company has determined not to pursue, at this time, the contemplated public offering to which the registration statement relates.
Benzinga · 08/22 11:13
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Benzinga · 08/18 21:33
BRIEF-Marker Therapeutics Reports Q2 2022 Operating And Financial Results
BRIEF-Marker Therapeutics Reports Q2 2022 Operating And Financial Results
Reuters · 08/11 21:35
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Investor Place · 08/08 11:29
Nasdaq Falls Over 100 Points, Marker Therapeutics Shares Spike Higher
U.S. stocks traded mostly lower toward the end of trading, following the release of jobs data
Benzinga · 08/05 19:06
Dow Drops 150 Points, Crude Oil Rises Over 2%
U.S. stocks traded lower midway through trading, following the release of jobs data
Benzinga · 08/05 16:02
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Investor Place · 08/05 11:29
BRIEF-Marker Therapeutics Announces FDA Clearance Of IND For MT-601 For Treatment Of Relapsed/Refractory Non-Hodgkin Lymphoma
BRIEF-Marker Therapeutics Announces FDA Clearance Of IND For MT-601 For Treatment Of Relapsed/Refractory Non-Hodgkin Lymphoma
Reuters · 08/04 21:51
Marker Therapeutics Shares Jump 60 Percent As FDA Announced Clearance To Blood Cell Cancer Study
The U.S. Food and Drug Administration (FDA) announced clearance to Marker Therapeutics’ (NASDAQ: MRKR) Investigational New Drug (IND) application for MT-601 for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma.
Benzinga · 08/04 21:01
More
Webull provides a variety of real-time MRKR stock news. You can receive the latest news about Marker Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About MRKR
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The Company has developed its lead product candidates from its MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (TAAs), which are tumor targets, and then kill tumor cells expressing those targets. It has three MultiTAA-specific T cell therapies through clinical development, which include Autologous MultiTAA-specific T cell therapies, Allogeneic MultiTAA-specific T cell therapies and Off-the-shelf MultiTAA-specific T cell therapies. The Company is focused on developing MT-601 for the treatment of advanced unresectable pancreatic cancer.